Euroopan unioni -
suomi -
EMA (European Medicines Agency)
incruse ellipta (previously incruse)
glaxosmithkline (ireland) limited - umeklidiniumbromidia - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - osoitettu hoidon bronkodilataattorikäsittelyksi oireiden lievittämiseksi aikuispotilailla, joilla on krooninen obstruktiivinen keuhkosairaus (copd).
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
incurin
intervet international bv - estrioli - sukupuolihormonit ja sukupuolielimen modulaattorit - koirat - hoito hormoni-riippuvainen virtsankarkailu johtuu sulkijalihaksen mekanismin kyvyttömyydestä heikkoudesta naaraskoirilla, joilta on ämmiä.
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
lincocin vet 100 mg/ml injektioneste, liuos
zoetis animal health aps - lincomycin hydrochloride monohydrate - injektioneste, liuos - 100 mg/ml - linkomysiini
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
provera 10 mg tabletti
pfizer oy - medroxyprogesterone acetate - tabletti - 10 mg - medroksiprogesteroni
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
majeptil 10 mg tabletti
rhone-poulenc rorer a/s - thioproperazini mesilas - tabletti - 10 mg - tioproperatsiini
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
majeptil 25 mg tabletti
rhone-poulenc rorer oy - thioproperazini mesilas - tabletti - 25 mg - tioproperatsiini
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. katso kohdat 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
pemazyre
incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastiset aineet - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.